Dasatinib is the only FDA-approved Src-Abl inhibitor, indicated for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia in patients who have failed first-line therapy [30,31]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.